Term of Research Collaboration Sample Clauses

Term of Research Collaboration. (i) The Selection Term will commence on the Effective Date and shall continue until the third (3rd) anniversary of the Effective Date (the "Selection Term"), which Selection Term may be extended for up to two (2) additional one- (1-) year periods, at Novartis's election upon the provision of written notice to Alnylam not later than ninety (90) calendar days prior to the end of the then current Selection Term. Notwithstanding the foregoing, the Selection Term may be terminated earlier pursuant to Sections 8.2 or 8.3.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Term of Research Collaboration. 25 11.1.2. Term of Agreement . . . . . . . . . . . . . 25 11.2. Events of Default . . . . . . . . . . . . . . . . 25 11.2.1. Default by Either Party . . . . . . . . . . 25 11.2.2. Default by SC . . . . . . . . . . . . . . . 25 11.3. Effect of an Event of Default . . . . . . . . . . 26 11.3.1. Remedies Available to GTC . . . . . . . . . 26 11.3.2. Remedies Available to SC . . . . . . . . . . 28 11.4. * SC . . . . . . . . . . . . . . . . . . 28 11.5. Effect of Expiration or Termination of Research Collaboration . . . . . . . . . . . . . . 28 11.6. Effect of Expiration or Termination of Agreement . . . . . . . . . . . . . . . . . . . . . 29 * Confidential information omitted and filed separately with the Commission
Sample 1Sample 2
Term of Research Collaboration. Except as otherwise provided in Section 12.1, the term of the Research Collaboration shall continue for a term of three (3)
Sample 1Sample 2
Term of Research Collaboration. Unless this Agreement is sooner terminated in accordance with the provisions of this Article 11, the term of the Research Collaboration shall expire * from the Funding Commencement Date; provided, however, that SC may, in its discretion, elect to extend the Research Collaboration for an additional * . SC shall deliver written notice to GTC at least * * prior to the expiration of the initial term of the Research Collaboration definitively stating whether SC intends to exercise its option to extend the term of the Research Collaboration. In any event, GTC may, in its discretion, engage in an orderly wind-down of the Research Collaboration, including the reassignment of the scientists devoted thereto, during the last * thereof.
Sample 1
Term of Research Collaboration. Section 2.3 of the Agreement is hereby deleted in its entirety and replaced by the following:
Sample 1
Term of Research Collaboration. Unless this Agreement is sooner terminated in accordance with the provisions of this Article 11, the term of the Research Collaboration shall expire at the end of the *...* Contract Year; PROVIDED, HOWEVER, that the Research Collaboration may be extended upon mutual agreement of the parties, reached no later than six (6) months prior to the end of the initial term of the Research Collaboration, for up to *...* additional periods of *...* Contract Year each. In any event, GTC may, in its discretion, engage in an orderly wind-down of the Research Collaboration, including the reassignment of the scientists devoted thereto, during the last six (6) months thereof. In such an event, the financial contribution of BMI to the Research Collaboration under the terms of Article 6.4.1 shall be adjusted accordingly but shall, in no event, for such six (6) month period, fall below the sum of *...* United States dollars (*...*) in accordance with the minimum research funding amount provided for under Section 6.4.1.
Sample 1
AutoNDA by SimpleDocs
Term of Research Collaboration. Unless this Agreement is sooner terminated in accordance with the provisions of this Article 11, the term of the Research Collaboration shall expire thirty (30) months from the Funding Commencement Date; provided, however, that SC may, in its discretion, elect to extend the Research Collaboration for an additional eighteen (18) months. SC shall deliver written notice to GTC at least * * prior to the expiration of the initial term of the Research Collaboration definitively stating whether SC intends to exercise its option to extend the term of the Research Collaboration. In any event, GTC may, in its discretion, engage in an orderly wind-down of the Research Collaboration, including the reassignment of the scientists devoted thereto, during the last * thereof.
Sample 1
Term of Research Collaboration. The term of the Research Collaboration shall be for [***] years (“Research Term”).
Sample 1

Related to Term of Research Collaboration

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Research Term The term “

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.